What is the treatment for Grade 1 hepatic encephalopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Grade 1 Hepatic Encephalopathy

The first-line treatment for Grade 1 hepatic encephalopathy is lactulose, with the dose titrated to achieve 2-3 soft bowel movements per day, alongside identification and correction of precipitating factors. 1, 2

Four-Pronged Management Approach

  1. Initial patient care and assessment

    • Patients with Grade 1 HE can typically be managed on a regular medical ward rather than requiring ICU admission 2
    • Perform systematic evaluation for signs of HE: asterixis, psychomotor slowing, sleep-wake inversion, temporospatial disorientation 2
    • Avoid sedatives when possible as they can worsen encephalopathy 2, 3
  2. Rule out alternative causes of altered mental status

    • Consider brain imaging to exclude other causes of decreased mental status 2
    • Normal ammonia levels should prompt diagnostic reevaluation 1
  3. Identify and correct precipitating factors

    • This is of paramount importance - nearly 90% of patients can be treated with just correction of precipitating factors 1, 2
    • Common precipitating factors include:
      • Infections
      • Gastrointestinal bleeding
      • Constipation
      • Dehydration
      • Electrolyte disturbances
      • Sedative medications 2, 4
  4. Specific pharmacological treatment

    • First-line: Lactulose

      • Initial dosing: 25 mL of lactulose syrup every 12 hours 1
      • Titrate dose to achieve 2-3 soft bowel movements per day 1, 2, 5
      • Mechanism: Acidifies the gastrointestinal tract, trapping ammonia as non-absorbable NH4+ in the colon 6
      • FDA-approved for prevention and treatment of portal-systemic encephalopathy 5
    • Second-line/Add-on: Rifaximin

      • Consider adding if inadequate response to lactulose alone 2, 7
      • Dosage: 550 mg orally twice daily 7
      • Mechanism: Decreases intestinal production and absorption of ammonia by altering gastrointestinal flora 8
      • FDA-approved for reduction in risk of overt HE recurrence 7

Important Considerations

  • Secondary prophylaxis: After the first episode of overt HE, secondary prophylaxis with lactulose is recommended 1, 2

  • Monitoring:

    • Perform frequent mental status checks 2
    • If condition progresses to Grade 2 encephalopathy, consider transfer to higher level of care 2
    • Monitor for metabolic abnormalities including glucose, potassium, magnesium, and phosphate levels 2
  • Liver transplantation evaluation:

    • The first episode of hepatic encephalopathy should prompt evaluation for liver transplantation 2
    • Recurrent intractable HE with liver failure is an indication for liver transplantation 1, 2

Common Pitfalls to Avoid

  • Failing to identify precipitating factors - this is the cornerstone of management and can resolve up to 90% of cases 1, 2

  • Inadequate lactulose dosing - ensure proper titration to achieve 2-3 soft bowel movements daily 1, 4

  • Relying solely on ammonia levels for diagnosis - ammonia levels alone do not add diagnostic, staging, or prognostic value 1, 2

  • Using benzodiazepines - these should be avoided as they can worsen encephalopathy and have delayed clearance in liver failure 2, 3

  • Not considering secondary prophylaxis after the first episode of overt HE 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hepatic Encephalopathy Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Sedation Options for Patients with Acute Liver Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Current trends in the treatment of hepatic encephalopathy.

Therapeutics and clinical risk management, 2009

Research

Lactulose enemas in the treatment of hepatic encephalopathy. Do we help or harm?

Revista espanola de enfermedades digestivas, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.